Interventions for Extracranial Carotid Artery Stenosis: An Update

详细信息查看全文

作者：Josephine F. Huang MD ; James F. Meschia MD
关键词：Carotid stenosis ; Carotid angioplasty and stenting ; Carotid endarterectomy ; Stroke prevention
刊名：Current Treatment Options in Cardiovascular Medicine
出版年：2016
出版时间：May 2016
年：2016
卷：18
期：5
全文大小：296 KB
参考文献：1.Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. New Engl J Med. 1991;325(7):445-53.
2.MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0–29%) carotid stenosis. European Carotid Surgery Trialists’ Collaborative Group. Lancet. 1991. 337(8752):1235-43.
3.Rothwell PM, Gutnikov SA, Warlow CP. Reanalysis of the final results of the European Carotid Surgery Trial. Stroke; J Cereb Circ. 2003;34(2):514–23.CrossRef
4.Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA. 1995;273(18):1421-8.
5.Eckstein HH et al. Results of the stent-protected angioplasty versus carotid endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol. 2008;7(10):893–902.CrossRef PubMed
6.Mas JL et al. Endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. Lancet Neurol. 2008;7(10):885–92.CrossRef PubMed
7.Brott TG et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363(1):11–23.CrossRef PubMed PubMedCentral
8.Silver FL et al. Safety of stenting and endarterectomy by symptomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). Stroke; J Cereb Circ. 2011;42(3):675–80.CrossRef
9.Bruckert E et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—cthe PRIMO study. Cardiovasc Drugs Ther / Int Soc Cardiovasc Pharmacother. 2005;19(6):403–14.CrossRef
10.Cohen JD et al. Understanding Statin use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15.CrossRef PubMed
11.Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 2000;22(6):441–57.CrossRef PubMed
12.Stroes ES et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–22.CrossRef PubMed PubMedCentral
13.Cannon CP, Blazing MA, Braunwald E. Ezetimibe plus a statin after acute coronary syndromes. N Engl J Med. 2015;373(15):1476–7.PubMed
14.Raal F et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126(20):2408–17.CrossRef PubMed
15.Sullivan D et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308(23):2497–506.CrossRef PubMed
16.Kohli P et al. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2012;35(7):385–91.CrossRef PubMed PubMedCentral
17.Koren MJ et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380(9858):1995–2006.CrossRef PubMed
18.Blom DJ et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809–19.CrossRef PubMed
19.Robinson JG et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–99.CrossRef PubMed
20.Navarese EP et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(1):40–51.CrossRef PubMed
21.Meschia JF et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke; J Cereb Circ. 2014;45(12):3754–832.CrossRef
22.Kernan WN et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke; J Cereb Circ. 2014;45(7):2160–236.CrossRef
23.Wright Jr JT et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.CrossRef PubMed
24.Cushman WC et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85.CrossRef PubMed
25.Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke; J Cereb Circ. 2009;40(10):e573–83.CrossRef
26.Spence JD et al. Effects of intensive medical therapy on microemboli and cardiovascular risk in asymptomatic carotid stenosis. Arch Neurol. 2010;67(2):180–6.CrossRef PubMed
27.Chimowitz MI et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365(11):993–1003.CrossRef PubMed PubMedCentral
28.Zaidat OO et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA. 2015;313(12):1240–8.CrossRef PubMed
29.Munster AB et al. Temporal trends in safety of carotid endarterectomy in asymptomatic patients: systematic review. Neurology. 2015;85(4):365–72.CrossRef PubMed
30.Rerkasem K, Rothwell PM. Patch angioplasty versus primary closure for carotid endarterectomy. Cochrane Database Syst Rev. 2009;4:CD000160.PubMed
31.Heyer EJ et al. Statins reduce neurologic injury in asymptomatic carotid endarterectomy patients. Stroke; J Cereb Circ. 2013;44(4):1150–2.CrossRef
32.Naylor AR et al. Closing the loop: a 21-year audit of strategies for preventing stroke and death following carotid endarterectomy. Eur J Vasc Endovasc Surg : Off J Eur Soc Vasc Surg. 2013;46(2):161–70.CrossRef
33.Yadav JS et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004;351(15):1493–501.CrossRef PubMed
34.•

Touze E et al. A clinical rule (sex, contralateral occlusion, age, and restenosis) to select patients for stenting versus carotid endarterectomy: systematic review of observational studies with validation in randomized trials. Stroke; J Cereb Circ. 2013;44(12):3394–400. The SCAR decision rule was validated with pooled data from SPACE, EVA-3S, and ICSS, and may be a useful tool in identifying patients who are at increased risk of CAS-related complications.CrossRef
35.Rothwell PM et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet. 2004;363(9413):915–24.CrossRef PubMed
36.Rantner B, et al. The risk of carotid artery stenting compared with carotid endarterectomy is greatest in patients treated within 7 days of symptoms. J Vasc Surg. 2013;57(3):619-626 e2; discussion 625-6.
37.Voeks JH et al. Age and outcomes after carotid stenting and endarterectomy: the carotid revascularization endarterectomy versus stenting trial. Stroke; J Cereb Circ. 2011;42(12):3484–90.CrossRef
38.Bonati LH, Fraedrich G. Age modifies the relative risk of stenting versus endarterectomy for symptomatic carotid stenosis—a pooled analysis of EVA-3S, SPACE and ICSS. Eur J Vasc Endovasc Surg : Off J Eur Soc Vasc Surg. 2011;41(2):153–8.CrossRef
39.Voeks JH et al. Mediators of the Age Effect in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). Stroke; J Cereb Circ. 2015;46(10):2868–73.CrossRef
40.Naggara O et al. Anatomical and technical factors associated with stroke or death during carotid angioplasty and stenting: results from the endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis (EVA-3S) trial and systematic review. Stroke; J Cereb Circ. 2011;42(2):380–8.CrossRef
41.Dumont TM et al. Understanding risk factors for perioperative ischemic events with carotid stenting: is patient age over 80 years or is unfavorable arch anatomy to blame? J Neurointerv Surg. 2014;6(3):219–24.CrossRef PubMed
42.••

Doig D, et al. Predictors of Stroke, Myocardial Infarction or Death within 30 Days of Carotid Artery Stenting: Results from the International Carotid Stenting Study. Eur J Vasc Endovasc Surg : the Off Jo Eur Soc Vasc Surg. 2015. Risk factors for stroke, MI, or death in patients enrolled in ICSS with symptomatic carotid stenosis >50% were investigated. There was an increased risk with increasing age, patients treated with open cell stent design, and in patients with atrial fibrillation. There was a decreased risk with current or former smokers, patients taking aspirin and clopidogrel prior to CAS, index event of amaurosis fugax, and right-sided procedures. The study highlights potential factors that may influence future risk-stratification of patients undergoing surgical carotid revascularization.
43.•

Ederle J et al. Effect of white-matter lesions on the risk of periprocedural stroke after carotid artery stenting versus endarterectomy in the International Carotid Stenting Study (ICSS): a prespecified analysis of data from a randomised trial. Lancet Neurol. 2013;12(9):866–72. The risk of all stroke or non-disabling stroke in patients with increased age-related white matter changes on preprocedural imaging was significantly higher in CAS-treated patients when compared to patients with less white matter changes. This was not seen in the CEA-treated patients, and suggests that preprocedural imaging can be useful in risk stratification of patients being considered for CAS.CrossRef PubMed PubMedCentral
44.Schnaudigel S et al. New brain lesions after carotid stenting versus carotid endarterectomy: a systematic review of the literature. Stroke; J Cereb Circ. 2008;39(6):1911–9.CrossRef
45.Bijuklic K et al. The PROFI study (Prevention of Cerebral Embolization by Proximal Balloon Occlusion Compared to Filter Protection During Carotid Artery Stenting): a prospective randomized trial. J Am Coll Cardiol. 2012;59(15):1383–9.CrossRef PubMed
46.Montorsi P et al. Microembolization during carotid artery stenting in patients with high-risk, lipid-rich plaque. A randomized trial of proximal versus distal cerebral protection. J Am Coll Cardiol. 2011;58(16):1656–63.CrossRef PubMed
47.Cano MN et al. Randomized comparison of distal and proximal cerebral protection during carotid artery stenting. J Am Coll Cardiol Intv. 2013;6(11):1203–9.CrossRef
48.Giri J et al. Proximal versus distal embolic protection for carotid artery stenting: a national cardiovascular data registry analysis. J Am Coll Cardiol Intv. 2015;8(4):609–15.CrossRef
49.Hart JP, et al. Do device characteristics impact outcome in carotid artery stenting? J Vasc Surg. 2006. 44(4):725-30; discussion 730-1.
50.Bosiers M, et al. Does free cell area influence the outcome in carotid artery stenting? Eur J Vasc Endovasc Surg : Off J Eur Soc Vasc Surg. 2007;33(2): p. 135-41; discussion 142-3.
51.Maleux G et al. Outcome of carotid artery stenting at 2 years follow-up: comparison of nitinol open cell versus stainless steel closed cell stent design. J Cardiovasc Surg. 2009;50(5):669–75.
52.Timaran CH, et al. Randomized clinical trial of open-cell vs closed-cell stents for carotid stenting and effects of stent design on cerebral embolization. J Vasc Surg. 2011;54(5):1310-1316 e1; discussion 1316.
53.Kwolek CJ et al. Results of the ROADSTER multicenter trial of transcarotid stenting with dynamic flow reversal. J Vasc Surg. 2015;62(5):1227–1234 e1.CrossRef PubMed

作者单位：Josephine F. Huang MD (1)
James F. Meschia MD (1)

1. The Department of Neurology (JFH, JFM), Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL, 32224, USA

刊物主题：Cardiology;

出版者：Springer US

ISSN：1534-3189